2023 Guidance and Q3 Earnings

2023 guidance at CER upgraded (excl. COVID-19 solutions) 2023 guidance 2023 sales guidance composition Vaccines Around 20% growth Sales Adj. operating profit Adj. earnings per share 12% to 13% growth Previously 8% to 10% growth 13% to 15% growth Previously 11% to 13% growth 17% to 20% growth Previously 14% to 17% growth Speciality Medicines¹ Low double-digit % growth HIV Around 10% growth General Medicines Low to mid single-digit % growth 2023 Arexvy considerations Q3 sales of £709m benefited from strong demand and initial channel inventory build, with TRx volumes representing ~1/3 volumes sold Correlation between influenza and RSV vaccination to date Expect full year sales of around £0.9-1bn, with further insight to be gained at the end of the 'flu season If exchange rates were to hold at the closing rates on 30 Sep 2023 ($1.23/£1, €1.16/£1 and Yen 183/£1) for the rest of 2023, the estimated impact on full-year 2023 Sterling turnover growth would be -2% and the estimated impact on Adjusted Operating Profit growth would be -4%. GSK All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statement in the Q3 2023 earnings release and the 2022 Annual Report. 1. including HIV 26 26

View entire presentation